en · de · es · pt
epitalon-notes.peptides3626.com › Wiki › Analytical Characterization And Stability — Explained

Analytical Characterization And Stability — Explained

By Editorial Desk · published 2025-12-19 · last reviewed 2026-02-05 · Wiki

Backbone hydrolysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2026-02-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

Analytical Characterization and Stability

Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.

Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.

Epitalon Background And Identification

The parent extract epithalamin was characterised as a low-molecular-weight fraction of pineal tissue rather than a single defined chemical entity. Researchers fractionated it and tested successive fragments for activity, a screening approach typical of peptide discovery work in that era. Epitalon emerged from that process as one of the shorter sequences of interest. Because the original extract was never fully resolved into individual components, claims about which constituent drives a given effect rest on inference. This distinction matters when reading older reports that attribute extract observations to the tetrapeptide itself.

Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.

Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.

Epitalon at a glance

PropertyValueNotes
Analytical methodReversed-phase HPLCPurity determination, typically 214 nm
Mass confirmationESI or MALDI mass spectrometryCompared with mass near 390 Da
Common synonymsEpitalon, epithalon, AEDGNaming differs between suppliers
Storage temperature−20 °C or lowerLyophilised powder, kept desiccated
Solution stabilityLimited in neutral aqueous bufferAspartimide and hydrolysis pathways

Laboratory Handling Storage and Analysis

Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection, frequently near 214 nanometers where the peptide bond absorbs. Mass spectrometry, most often with electrospray ionization, confirms the observed molecular mass and helps separate the intact peptide from truncated or modified forms. Amino acid analysis or tandem mass spectrometry can establish residue order. Purity is commonly quoted as an area percentage, yet such values are method-dependent, and comparisons between laboratories require matching column, gradient and detection wavelength.

Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.

Related pages on this site

Identity and Research Background

Published work on this compound consists mainly of in vitro experiments, animal studies, and small clinical investigations, a substantial share of which appeared in Russian-language journals. Sample sizes are generally small, control conditions differ between studies, and several endpoints rely on markers whose clinical meaning is itself debated. Reviews of the longevity field treat the peptide as an early example of telomerase-directed research rather than an established intervention. Regulatory treatment varies by country: some jurisdictions place it under prescription controls, others treat it as a laboratory material, and importation may be restricted regardless of local status.

Epitalon is a synthetic tetrapeptide whose sequence is alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. It was developed in Russia during the 1980s and 1990s by investigators associated with the St. Petersburg Institute of Bioregulation and Gerontology, who studied short peptides as regulators of gene expression and tissue function. The alternative spelling epithalon appears interchangeably in the literature, and the two names refer to the same molecule. Outside Russia it is encountered chiefly as a research chemical rather than a licensed medicine, and it holds no approval from the United States Food and Drug Administration or the European Medicines Agency.

The peptide is a synthetic analogue of epithalamin, a preparation extracted from bovine pineal glands. Investigators sought a short, chemically defined molecule that would reproduce some of the endocrine and gerontological observations attributed to the glandular extract. Proposed mechanisms centre on induction of telomerase activity, an effect reported in cultured human somatic cells in the early 2000s, together with influences on melatonin secretion and neuroendocrine regulation. Those mechanisms remain incompletely characterised, and the reported telomerase response has not been consistently reproduced by independent groups working in comparable systems.

Reference notes

== Research == The use of a nitric oxide delivery system (glyceryl trinitrate patches) applied over the area of maximal tenderness was found to reduce pain and increase range of motion and strength. A promising therapy involves eccentric loading exercises involving lengthening muscular contractions.

Oxford or Florey unit (1941). This was originally defined as the minimum amount of penicillin dissolved in 50 ml of meat extract that would inhibit the growth of a standard strain of Staphylococcus aureus (the Oxford Staphylococcus). The reference standard was a large batch of impure penicillin kept in Oxford. The assay was later modified by Florey's group to a more reproducible "cup assay": in this assay, a penicillin solution was defined to contain one unit/ml of penicillin when 339 microlitres of the solution placed in a "cup" on a plate of solid agar produced a 24 millimetre zone of inhibition of growth of Oxford Staphylococcus. First International Standard (1944). A single 8 gram batch of pure crystalline penicillin G sodium was stored at The National Institute for Medical Research in Mill Hill, London (the International Standard). One penicillin unit was defined at 0.6 micrograms of the International Standard. An impure "working standard" was also defined and was available in much larger quantities distributed around the world: one unit of the working standard was 2.7 micrograms (the amount per unit was much larger because of the impurities). At the same time, the cup assay was refined, where instead of specifying a zone diameter of 24 mm, the zone size were instead plotted against a reference curve to provide a readout on potency. Second International Standard (1953). A single 30 gram batch of pure crystalline penicillin G sodium was obtained: this was also stored at Mill Hill.

== Anatomy == The blood–brain barrier is formed by special tight junctions between endothelial cells lining brain blood vessels. Blood vessels of all tissues contain this monolayer of endothelial cells, however only brain endothelial cells have tight junctions preventing passive diffusion of most substances into the brain tissue. The structure of these tight junctions was first determined in the 1960s by Tom Reese, Morris Kranovsky, and Milton Brightman. Furthermore, astrocytic "end feet", the terminal regions of the astrocytic processes, surround the outside of brain capillary endothelial cells". The astrocytes are glial cells restricted to the brain and spinal cord and help maintain blood-brain barrier properties in brain endothelial cells.

=== The Buck Institute for Research on Aging === In November 2016, Verdin became president and CEO of the Buck Institute for Research on Aging. The Buck Institute is the first independent research center focused solely on aging. As of 2022, it had an operating budget of $65 million a year and around 300 employees. The Buck's first human clinical trial, Buck Institute Ketone Ester (BIKE), was announced in 2023. In 2025, Verdin was named a scientific ambassador for Alliance for Longevity Science, Arts & Entertainment (ALSAE), a partner organization of the Buck Institute.

Evolution of Aschoff nodules typically involve 3 stages of development all of which may be present in the heart at the same time of inspection. Stage 1. Early exudative / degenerative stage the earliest sign of injury to the heart in rheumatic fever is apparent by fourth week of illness. Initially there is edema of the connective tissue and increase in acid mucopolysaccharide in the ground substance. This results in a separation of the collagen fibre by accumulating ground substance eventually the collagen fibres are fragmented and disintegrated and the affected focus takes the appearance and staining characteristics of fibrin. Stage 2. Intermediate proliferative / granulomatous stage. It is at this stage of Aschoff bodies, which is pathognomonic of rheumatic fever. This stage is apparent in 4 to 13 weeks of illness. The early stage of fibrinoid change is replaced by infiltration of lymphocyte T cells, plasma cells, neutrophils and the characteristic cardiac histiocytes / Anitschkow cells at the margin of the lesion. Cardiac Histiocytes / Anitschkow are present in small numbers in the heart but their numbers are increased in Aschoff nodules. therefore they are not characteristic of rheumatic heart disease Stage 3. Late fibrosis stage. It is the stage of healing by which the fibrosis of the Aschoff nodules occur in 12 to 16 weeks after the illness. The nodule becomes oval or fusiform in shape about 200 micrometer x 600 micrometer in width and length. With passage of months and years the Aschoff nodules becomes less cellular and collagenous tissue is increased.

Sources: en.wikipedia.org

Notes from published material

== Regulation == Central to the physiologic maintenance of GFR is the differential vasoconstriction of the afferent (input) and efferent (output) arterioles. Vasodilation of the afferent or vasoconstriction of the efferent arteriole increases GFR. Conversely, vasoconstriction of the afferent or vasodilation of the efferent will decrease GFR. There are multiple mechanisms that the body has to regulate the constriction or dilation of these arterioles: local feedback within the kidney, hormonal regulation, and sympathetic nervous control. These systems are closely intertwined. The kidney can maintain a relatively constant GFR even as mean arterial pressure changes. Local feedback within the kidney (renal autoregulation) includes the myogenic response and tuberoglomerular feedback. In the myogenic response, increased stretch of the afferent arteriole due to higher blood pressure results in afferent vasoconstriction, thereby preventing an increase in GFR. With tuberoglomerular feedback, the macula densa cells at the downstream nephron tubule senses changes in ion levels. If sodium chloride sodium levels in the urinary filtrate are too high, the macula densa signals to constrict the afferent arteriole; if too low, the signal is to vasodilate the afferent arteriole and to release renin (activating the RAAS system). The RAAS system is the major hormonal control of GFR. Low blood pressure activates the RAAS system, increasing the amount of the hormone angiotensin II. Angiotensin II binds to receptors on the efferent arteriole; the resulting efferent vasoconstriction increases GFR.

=== Post-WW2 20th century === In the 1960s, production abroad was expanded and plants were built in Argentina, Australia, Belgium, Brazil, France, India, Italy, Japan, Mexico, Spain, United Kingdom and the United States. Following a change in corporate strategy in 1965, greater emphasis was placed on higher-value products such as coatings, pharmaceuticals, pesticides and fertilizers. Following German reunification, BASF acquired a site in Schwarzheide, Eastern Germany, on 25 October 1990. In 1968, BASF (together with Bayer AG) bought the German coatings company Herbol. BASF completely took over the Herbol branches in Cologne and Würzburg in 1970. Under new management, the renewal and expansion of the trademark continued. After an extensive reorganisation and an increasing international orientation of the coatings business, Herbol became part of the new founded Deco GmbH in 1997. BASF bought the Wyandotte Chemical Company, and its Geismar, Louisiana chemical plant in the early 1970s. The plant produced plastics, herbicides, and antifreeze. BASF soon tried to operate union-free, having already reduced or eliminated union membership in several other US plants. Challenging the Geismar OCAW union resulted in a labor dispute that saw members locked out from 1984 to 1989, and eventually winning their case. A worker solidarity committee at BASF's headquarters plant in Ludwigshafen, Germany, took donations from German workers to support the American strikers and organized rallies and publicity in support. The dispute was the subject of an academic study.

==== β-carotene safety ==== No adverse effects other than carotenemia have been reported for consumption of β-carotene rich foods. Supplementation with β-carotene does not cause hypervitaminosis A. Two large clinical trials (ATBC and CARET) were conducted in tobacco smokers to see if years of β-carotene supplementation at 20 or 30 mg/day in oil-filled capsules would reduce the risk of lung cancer. These trials were implemented because observational studies had reported a lower incidence of lung cancer in tobacco smokers who had diets higher in β-carotene. Unexpectedly, high-dose β-carotene or retinol supplementation resulted in a higher incidence of lung cancer and of total mortality due to cardiac mortality. Taking this and other evidence into consideration, the U.S. Institute of Medicine decided not to set a Tolerable Upper Intake Level (UL) for β-carotene. The European Food Safety Authority, acting for the European Union, also decided not to set a UL for β-carotene.

=== Costs === A lower number of available therapeutic options correlates with higher prices. In addition, many first-in-class medications are specialty drugs and orphan drugs, which means that manufacturers have to recoup development costs from a smaller market. This raises ethical questions about the sustainability of the high prices on these costs.

Downtown Emergency Service Center (DESC), in Seattle, Washington, operates several Housing First programmes which utilize the harm reduction model. University of Washington researchers, partnering with DESC, found that providing housing and support services for homeless alcoholics costs taxpayers less than leaving them on the street, where taxpayer money goes towards police and emergency health care. Results of the study funded by the Substance Abuse Policy Research Program (SAPRP) of the Robert Wood Johnson Foundation appeared in the Journal of the American Medical Association in April 2009. This first controlled assessment in the U.S. of the effectiveness of Housing First, specifically targeting chronically homeless alcoholics, showed that the programme saved taxpayers more than $4 million over the first year of operation. During the first six months, the study reported an average cost-savings of 53 percent (even after considering the cost of administering the housing's 95 residents)—nearly $2,500 per month per person in health and social services, compared to the per month costs of a wait-list control group of 39 homeless people. Further, despite the fact residents are not required to be abstinent or in treatment for alcohol use, stable housing also results in reduced drinking among people experiencing homelessness who recreationally use alcohol.

Sources: en.wikipedia.org

Frequently asked questions

Why is ultraviolet detection at 214 nanometres used?

The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.

What conditions degrade epitalon in solution?

Neutral and slightly basic aqueous conditions promote aspartimide formation at the aspartate-glycine step, often followed by deamidation. Elevated temperature and repeated freeze-thaw cycles accelerate the loss. Acidic solutions and dry lyophilised powder are comparatively stable over short periods.

Is there a pharmacopoeial standard for epitalon?

No monograph exists in the United States Pharmacopeia or the European Pharmacopoeia, and no widely distributed certified reference standard is available. Purity and identity therefore rest on supplier methods that are not harmonised. This absence is the main reason reported purities are difficult to compare between sources.

What is epitalon derived from?

It is based on epithalamin, a peptide-rich preparation obtained from pineal gland tissue and studied in the former Soviet Union. Researchers later identified the tetrapeptide AEDG as a constituent fragment of that material. Modern supplies are produced by chemical synthesis rather than tissue extraction.

Network